Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
Recruiting now
Conditions studied: Glioma
In brief
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine histopathology image based algorithms that are able to predict molecular pathology or subgroups of gliomas.
Key facts
- Study ID
- NCT04217044
- Run by
- The First Affiliated Hospital of Zhengzhou University
- People needed
- 3000
- Starts
- 2017-01-01
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2021-02-08
Who can join
Age: 1 and older, up to 95. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Patients must have radiologically and histologically confirmed diagnosis of primary glioma
- Life expectancy of greater than 3 months
- Must receive tumor resection
- Signed informed consent
You may not qualify if…
- No gliomas
- No sufficient amount of tumor tissues for detection of molecular pathology
- Patients who are pregnant or breast feeding
- Patients who are suffered from severe systematic malfunctions
Where it is running
- Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.